48
Participants
Start Date
December 31, 2024
Primary Completion Date
June 30, 2031
Study Completion Date
June 30, 2034
Atezolizumab & Bevacizumab
Atezolizumab \& Bevacizumab will be initiated as part of the study, as per standard treatment protocol. Administration of Atezolizumab and Bevacizumab will be performed according to SOC in approx. 21-days intervals. Clinical follow up during treatment will be done as per SOC in medical and surgical oncology clinics at UHN.
Yttrium-90 (Y-90)
Storage, administration and treatment of Y90-RE will be done according to established treatment protocols and standard of care at UHN.
Stereotactic body radiotherapy (SBRT)
Dose and administration frequency of SBRT will be done as per current standards for treating HCC at UHN.
NOT_YET_RECRUITING
London Health Sciences Centre, London
RECRUITING
Toronto General Hospital, Toronto
University Health Network, Toronto
OTHER